Crossmark

Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission

Crossref DOI link: https://doi.org/10.1016/j.gastre.2017.07.010

Published Print: 2017-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Guerrero Puente, Lourdes

Iglesias Flores, Eva

Benítez, José Manuel

Medina Medina, Rosario

Salgueiro Rodríguez, Isabel

Aguilar Melero, Patricia

Cárdenas Aranzana, Manuel Jesús

González Fernández, Rafael

Manzanares Martin, Bárbara

García-Sánchez, Valle
License Information

Text and Data Mining valid from 2017-11-01
More Information

This article is maintained by: Elsevier

Article Title: Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2017.07.010

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2017.07.005

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. All rights reserved.